Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2025)

Historic Revenue for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to $239.5 million.

  • Harmony Biosciences Holdings' Revenue rose 2871.3% to $239.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $825.9 million, marking a year-over-year increase of 2112.76%. This contributed to the annual value of $714.7 million for FY2024, which is 2280.19% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Revenue stood at $239.5 million, which was up 2871.3% from $200.5 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Revenue's 5-year high stood at $239.5 million during Q3 2025, with a 5-year trough of $59.7 million in Q1 2021.
  • Over the past 5 years, Harmony Biosciences Holdings' median Revenue value was $134.2 million (recorded in 2023), while the average stood at $140.2 million.
  • In the last 5 years, Harmony Biosciences Holdings' Revenue skyrocketed by 20077.62% in 2021 and then surged by 1601.43% in 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Revenue (Quarter) stood at $91.2 million in 2021, then skyrocketed by 40.67% to $128.3 million in 2022, then skyrocketed by 31.26% to $168.4 million in 2023, then rose by 19.51% to $201.3 million in 2024, then rose by 18.97% to $239.5 million in 2025.
  • Its last three reported values are $239.5 million in Q3 2025, $200.5 million for Q2 2025, and $184.7 million during Q1 2025.